Available datapackage for study 'Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo'

Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized
by progressive decline in cognitive function and ability to perform activities of daily
living, and ultimately can lead to death due to complications of the disease. AD is thought
to be caused by an excess of A-Beta amyloid, a sticky protein in the brain that forms amyloid
plaques. Treatments that slow the synthesis or deposition of A-Beta amyloid, or that increase
clearance, might be expected to slow the progression of AD.

LY2062430 (solanezumab) is a humanized anti-A Beta peptide immunoglobulin G-1 (IgG1)
monoclonal antibody being developed for the treatment of AD. The primary hypothesis being
tested is that LY2062430 will slow cognitive and functional decline in AD as compared with
placebo. Each patient's participation will last approximately 19 months. Patients taking
approved AD medications may participate in this study and continue taking these medications
during the study.